Home
Storia in 2 fonti
Biotech group’s shares hit by weight-loss drug setback
Zealand Pharma falls 32% following mid-stage trial results for treatment being developed with Roche
- ·
ft.com
Biotech group’s shares hit by weight-loss drug setback
Zealand Pharma falls 32% following mid-stage trial results for treatment being developed with Roche
- ·
cnbc.com
Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics'
Zealand and Roche are jointly developing the drug petrelintide which in a mid-stage study led to a worse-than-expected 10.7% weight-loss over 42 weeks.